Global periodontal therapeutic market is set to witness a strong growth in the forthcoming years. The latest study conducted by Market Research Future (MRFR) reveals that the global periodontal therapeutic market will surge at 9.2% CAGR during 2018 to 2023.
Periodontal continues to be one of the major causes of tooth loss and a major oral health issue. The disease is common in both developed and developing countries, affecting nearly 20 to 50% of the global population. Over the years, different periodontal therapies have come up with a high degree of effectivity. Both surgical and non-surgical treatment options available.
The onset of periodontal issues could be triggered by poor oral hygiene, diabetes mellitus, stress, smoking and hormonal changes in females. The incidence rate has continued to grow, which is also driving the demand for periodontal therapeutic. As per World Health Organization (WHO), there is a high incident rate of gingival bleeding in adults worldwide. Meanwhile, 10 to 15% of adults are affected with deep periodontal pockets (6 mm or more) globally.
Major drivers of the global periodontal therapeutic market include rising geriatric population and growing worldwide healthcare spending. Nevertheless, poor level of awareness and negligence towards oral hygiene, especially in third-world countries are among the key bottlenecks for the market.
The segmental analysis on the global periodontal therapeutic market is based on treatment, type and end-users.
By treatment, the market has bees segmented into local antibiotics and systematic antibiotics. The local antibiotics segment is further segmented into chlorhexidine, arestin and others. The systematic antibiotics segment is further sub-segmented into metronidazole, minocycline, doxycycline and others. Based on type, the market has been segmented into aggressive periodontitis, chronic periodontitis, gingivitis and necrotizing periodontal disease. By end-user, the market has been segmented into hospitals and dental clinics
Global Periodontal Therapeutic Market: Regional Segmentation
Key regions covered in MRFR’s report include Asia Pacific, Europe, North America and the Middle East and Africa (MEA). In terms of revenue, North America accounts for the predominant market share. This is mainly owing to the higher prevalence of periodontal diseases among the elderly population in countries such the U.S. and Canada. The data released by the Centers for Disease Control and Prevention (CDC) reveals that nearly 50% of people in the U.S. aged 30 of older suffer from periodontitis as advanced form of periodontal disease. This is equivalent to around 64.7 Mn American with periodontal diseases.
Europe is also viewed as an important market for periodontal therapeutic. The prevalence rate in Europe has increased in recent years. Factors such as an expanding elderly population, availability of advanced healthcare services and effective reimbursement policies are playing an important role in driving the market growth in Europe. The market in Europe is expected to exhibit a steady growth during the forecast period.
Asia Pacific is the third largest market for periodontal therapeutic and is expected to witness a strong growth over the next couple of years. A large patient population coupled with increasing healthcare expenditure will create significant opportunities for the market to grow in APAC during the forecast period.
The MEA market holds significant potentials for growth with GCC countries at the forefront of it. Rising standard of healthcare, growing level of awareness and introduction of favourable policies are factors propelling the market in MEA.
Some of the leading companies operating in the global periodontal therapeutic market include Tolmar Inc., Align Technology Inc., 3M-ESPE, Nobel Biocare Holdings AG, Orapharma, Valeant Pharmaceuticals Int. Inc., Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries Limited., Ultradent Products Inc., Eli Lilly Company, Glidewell Laboratories, Inc., Den-Mat Holdings., Purdue Pharma L.P., Kaken Pharmaceutical, Dentsply International and Fibrocell Sciences, Inc,.